Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.

Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
复制标题

乳腺癌 1 中扩增的下调有助于索拉非尼对人肝细胞癌的抗肿瘤作用。

DOI:
10.18632/oncotarget.8812
复制
发表时间:
2016-05-17
期刊:
影响因子:
--
通讯作者:
Yu C
Yu C
中科院分区:
其他
文献类型:
--
作者:
Li M;Wang W;Dan Y;Tong Z;Chen W;Qin L;Liu K;Li W;Mo P;Yu C

文献摘要

参考文献

被引文献

相似文献

多激酶抑制剂索拉非尼是治疗晚期肝细胞癌(HCC)的重大突破。乳腺癌扩增1(AIB 1)经常在人HCC组织中过表达,并促进HCC进展。在这项研究中,我们研究了索拉非尼对AIB 1表达的影响以及AIB 1在索拉非尼抗肿瘤作用中的作用。我们发现索拉非尼通过同时阻断eIF 4 E和mTOR/p70 S6 K/RP-S6信号转导抑制AIB 1 mRNA翻译来下调AIB 1蛋白表达。AIB 1的敲低显著促进索拉非尼诱导的细胞死亡,而AIB 1的过表达显著减少索拉非尼诱导的细胞死亡。AIB 1的下调至少部分通过上调HCC细胞中活性氧的水平来促进索拉非尼诱导的细胞死亡。此外,对索拉非尼诱导的AIB 1蛋白下调的抗性有助于HCC细胞对索拉非尼诱导的细胞死亡的获得性抗性。总的来说,我们的研究表明,AIB 1是索拉非尼的分子靶点,AIB 1的下调有助于索拉非尼的抗肿瘤作用。
Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced hepatocellular carcinoma (HCC). Amplified in breast cancer 1 (AIB1) is frequently overexpressed in human HCC tissues and promotes HCC progression. In this study, we investigated the effects of sorafenib on AIB1 expression and the role of AIB1 in anti-tumor effects of sorafenib. We found that sorafenib downregulated AIB1 protein expression by inhibiting AIB1 mRNA translation through simultaneously blocking eIF4E and mTOR/p70S6K/RP-S6 signaling. Knockdown of AIB1 significantly promoted sorafenib-induced cell death, whereas overexpression of AIB1 substantially diminished sorafenib-induced cell death. Downregulation of AIB1 contributed to sorafenib-induced cell death at least in part through upregulating the levels of reactive oxygen species in HCC cells. In addition, resistance to sorafenib-induced downregulation of AIB1 protein contributes to the acquired resistance of HCC cells to sorafenib-induced cell death. Collectively, our study implicates that AIB1 is a molecular target of sorafenib and downregulation of AIB1 contributes to the anti-tumor effects of sorafenib.
DOI: 10.1056/nejmoa0708857
发表时间: 2008-07-24
影响因子: 158.5
作者:
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者: Bruix, Jordi
DOI: 10.1016/j.bbrc.2012.01.060
发表时间: 2012-02-17
影响因子: 3.1
作者:
Li, Xi-feng;Gong, Ren-yan;Shi, Le-hua
通讯作者: Shi, Le-hua
DOI: 10.1158/0008-5472.can-04-1443
发表时间: 2004-10-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Wilhelm, SM;Carter, C;Trail, PA
通讯作者: Trail, PA
DOI: 10.1101/gr.gr-1460r
发表时间: 2000-11-01
期刊: GENOME RESEARCH
影响因子: 7
作者:
Davuluri, RV;Suzuki, Y;Zhang, MQ
通讯作者: Zhang, MQ
DOI: 10.1158/0008-5472.can-05-0808
发表时间: 2006-02-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Panka, DJ;Wang, W;Mier, JW
通讯作者: Mier, JW